Non-injectable delivery of fragile biologics into skin
​
ExoGenis is developing a new type of microneedle delivery system designed to place biologically active ingredients (such as extracellular vesicles, growth factors, peptides, complex proteins) beyond the skin surface without injections.
​
The technology is initially being developed for professional cosmetic and aesthetic applications, while being designed to remain compatible with future clinical and pharmaceutical development pathways.
Launching with clinical partners in 2026
The Problem
​​
Delivery, not ingredients, limits performance.
​
Many biologically active ingredients used in advanced skin applications are fragile and unable to cross the skin barrier on their own.
​
When applied topically, they largely remain on the surface and may degrade before reaching deeper skin layers. Injectable approaches can bypass this barrier, but they are invasive, operator-dependent, and not suitable or desirable for many use cases.
​
As a result, the effectiveness of biologic skin treatments is often constrained by delivery method rather than ingredient potential.
The Approach
​​
We developed a controlled placement without injections, which enables placement of biologically active ingredients beyond the skin surface without the use of traditional injections.
​
Why this matters: Bridging topical and injectable approaches
​
By removing the need for injections, ExoGenis aims to expand access to delivery methods that have traditionally been limited to clinical settings.
​
The technology is positioned between topical skincare and injectable treatments, enabling professional cosmetic use today while allowing for future expansion into regulated clinical contexts as data and validation mature.
Current Status
Where we are now?
​
The system has reached validated prototype stage.
Development is progressing in collaboration with US-based partners, supporting process optimization, reproducibility, and early manufacturing readiness.
​
Technical validation work is being conducted in Denmark.
​
In parallel, ExoGenis is preparing pilot programs with selected aesthetic and dermatology clinics in Europe and the UK in 2026